PE8697A1 - Procedimiento de preparacion del trihidrato de(2r,3s)-3-tert-butoxicarbonilamino -2-hidroxi-3-fenilpropionato de 4-acetoxi-2o-benzoiloxi-5�,20-epoxi-1,7�,10�-trihidroxi -9-oxo-tax-11-en-13o-ile - Google Patents

Procedimiento de preparacion del trihidrato de(2r,3s)-3-tert-butoxicarbonilamino -2-hidroxi-3-fenilpropionato de 4-acetoxi-2o-benzoiloxi-5�,20-epoxi-1,7�,10�-trihidroxi -9-oxo-tax-11-en-13o-ile

Info

Publication number
PE8697A1
PE8697A1 PE1995272899A PE27289995A PE8697A1 PE 8697 A1 PE8697 A1 PE 8697A1 PE 1995272899 A PE1995272899 A PE 1995272899A PE 27289995 A PE27289995 A PE 27289995A PE 8697 A1 PE8697 A1 PE 8697A1
Authority
PE
Peru
Prior art keywords
beta
tax
oxo
tert
phenylpropionate
Prior art date
Application number
PE1995272899A
Other languages
English (en)
Inventor
Mandard Bernadette
Fouque Elie
Rene Authelin Jean
Doveze Jacques
Taillepied Isabelle
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465183&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE8697(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of PE8697A1 publication Critical patent/PE8697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

QUE SE CARACTERIZA POR: a) LA CRISTALIZACION DEL (2R,3S)-3-TERT-BUTOXICARBONILAMINO-2-HIDROXI-3-FENILPROPIONATO DE 4-ACETOXI-2O-BENZOILOXI-5�,20-EPOXI-1,7�, 10�-TRIHIDROXI-9-OXO-TAX-11-EN-13O-ILE, EN UNA MEZCLA DE AGUA Y ALCOHOL ALIFATICO QUE CONTIENE DE UNO A TRES ATOMOS DE CARBONO, EN PROPORCION DE 2/1, DE PREFERENCIA EL ALCOHOL ES ETANOL, EN PRESENCIA DE ACIDO ASCORBICO; Y b) EL SECADO DEL PRODUCTO OBTENIDO BAJO LAS CONDICIONES DETERMINADAS DE TEMPERATURA TALES COMO 40�C, HUMEDAD RELATIVA APROXIMADA A 80% Y PRESION DE 4KPa A 7KP. ESTE COMPUESTO SE CARACTERIZA POR SUS PROPIEDADES ANTICANCEROSAS Y ANTILEUCEMICAS
PE1995272899A 1994-07-08 1995-07-05 Procedimiento de preparacion del trihidrato de(2r,3s)-3-tert-butoxicarbonilamino -2-hidroxi-3-fenilpropionato de 4-acetoxi-2o-benzoiloxi-5�,20-epoxi-1,7�,10�-trihidroxi -9-oxo-tax-11-en-13o-ile PE8697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9408479A FR2722191B1 (fr) 1994-07-08 1994-07-08 Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle

Publications (1)

Publication Number Publication Date
PE8697A1 true PE8697A1 (es) 1997-03-26

Family

ID=9465183

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995272899A PE8697A1 (es) 1994-07-08 1995-07-05 Procedimiento de preparacion del trihidrato de(2r,3s)-3-tert-butoxicarbonilamino -2-hidroxi-3-fenilpropionato de 4-acetoxi-2o-benzoiloxi-5�,20-epoxi-1,7�,10�-trihidroxi -9-oxo-tax-11-en-13o-ile

Country Status (38)

Country Link
US (1) US6022985A (es)
EP (1) EP0770070B1 (es)
JP (1) JP3753155B2 (es)
KR (1) KR100391753B1 (es)
CN (1) CN1067996C (es)
AT (1) ATE171702T1 (es)
AU (1) AU706519B2 (es)
BR (1) BR9508789A (es)
CA (1) CA2193531C (es)
CO (1) CO4410189A1 (es)
CZ (1) CZ284695B6 (es)
DE (1) DE69505128T2 (es)
DK (1) DK0770070T3 (es)
DZ (1) DZ1905A1 (es)
ES (1) ES2121404T3 (es)
FI (1) FI119246B (es)
FR (1) FR2722191B1 (es)
GR (1) GR3027558T3 (es)
HU (1) HU220634B1 (es)
IL (1) IL114274A (es)
IN (1) IN183947B (es)
IS (1) IS2032B (es)
MA (1) MA23606A1 (es)
MX (1) MX9700173A (es)
MY (1) MY118481A (es)
NO (1) NO314500B1 (es)
NZ (1) NZ289455A (es)
PE (1) PE8697A1 (es)
PL (1) PL179876B1 (es)
RU (1) RU2126397C1 (es)
SI (1) SI0770070T1 (es)
SK (1) SK280520B6 (es)
TN (1) TNSN95071A1 (es)
TW (1) TW419473B (es)
UA (1) UA51624C2 (es)
UY (1) UY23991A1 (es)
WO (1) WO1996001815A1 (es)
ZA (1) ZA955646B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL336523A1 (en) 1997-04-28 2000-07-03 Rhone Poulenc Rorer Sa Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
US6853921B2 (en) 1999-07-20 2005-02-08 Halliburton Energy Services, Inc. System and method for real time reservoir management
US6266619B1 (en) * 1999-07-20 2001-07-24 Halliburton Energy Services, Inc. System and method for real time reservoir management
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6891050B2 (en) * 2001-08-10 2005-05-10 Dabur India Limited Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6838569B2 (en) * 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US7584165B2 (en) * 2003-01-30 2009-09-01 Landmark Graphics Corporation Support apparatus, method and system for real time operations and maintenance
US8703982B2 (en) * 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1947094A3 (en) 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
US7142986B2 (en) * 2005-02-01 2006-11-28 Smith International, Inc. System for optimizing drilling in real time
CN100420681C (zh) * 2005-04-29 2008-09-24 上海奥锐特国际贸易有限公司 多烯紫杉醇三水物的制备方法
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
NZ566705A (en) 2005-08-31 2011-06-30 Abraxis Bioscience Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP1819688A2 (en) * 2005-10-12 2007-08-22 Sicor, Inc. Crystalline forms of docetaxel and processes for their preparation
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
WO2007084611A2 (en) * 2006-01-20 2007-07-26 Landmark Graphics Corporation Dynamic production system management
US20100160653A1 (en) * 2006-03-21 2010-06-24 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
JP2010506932A (ja) * 2006-10-20 2010-03-04 シノファーム シンガポール ピーティーイー，リミテッド 結晶性の無水ドセタキセルの製造方法
KR100868116B1 (ko) 2007-04-09 2008-11-10 한미약품 주식회사 도세탁셀·모노프로필렌글라이콜 내포화합물 및 이의제조방법
KR100878455B1 (ko) * 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
US20100197944A1 (en) * 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
ES2389518T3 (es) * 2008-01-18 2012-10-26 Indena S.P.A. Formas sólidas de ortataxel
EP2080763A1 (en) * 2008-01-18 2009-07-22 INDENA S.p.A. Crystalline form I of ortataxel
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012160568A1 (en) * 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc TARGETING THE PATHWAY FROM GLUTAMINE TO PYRUVATE TO TREAT CANCER ASSOCIATED WITH ONCOGEN KRAS
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides

Also Published As

Publication number Publication date
BR9508789A (pt) 1997-10-21
FI970069A (fi) 1997-01-07
ZA955646B (en) 1996-02-21
MY118481A (en) 2004-11-30
DE69505128T2 (de) 1999-04-01
PL179876B1 (pl) 2000-11-30
WO1996001815A1 (fr) 1996-01-25
MX9700173A (es) 1997-04-30
NO970007D0 (no) 1997-01-02
FR2722191B1 (fr) 1996-08-23
PL318195A1 (en) 1997-05-26
HUT76833A (en) 1997-11-28
CN1067996C (zh) 2001-07-04
CA2193531A1 (fr) 1996-01-25
DE69505128D1 (de) 1998-11-05
SK697A3 (en) 1997-06-04
SK280520B6 (sk) 2000-03-13
KR970704721A (ko) 1997-09-06
CZ3597A3 (en) 1997-04-16
HU9700041D0 (en) 1997-02-28
IL114274A0 (en) 1995-10-31
IL114274A (en) 1999-04-11
TNSN95071A1 (fr) 1996-02-06
NO970007L (no) 1997-01-02
DZ1905A1 (fr) 2002-02-17
ATE171702T1 (de) 1998-10-15
JP3753155B2 (ja) 2006-03-08
FI119246B (fi) 2008-09-15
EP0770070B1 (fr) 1998-09-30
UY23991A1 (es) 1995-09-20
NZ289455A (en) 1997-12-19
AU706519B2 (en) 1999-06-17
GR3027558T3 (en) 1998-11-30
US6022985A (en) 2000-02-08
JPH10502627A (ja) 1998-03-10
ES2121404T3 (es) 1998-11-16
MA23606A1 (fr) 1996-04-01
NO314500B1 (no) 2003-03-31
IS2032B (is) 2005-08-15
IN183947B (es) 2000-05-20
CA2193531C (fr) 2006-12-05
KR100391753B1 (ko) 2004-02-11
FR2722191A1 (fr) 1996-01-12
CO4410189A1 (es) 1997-01-09
CZ284695B6 (cs) 1999-02-17
UA51624C2 (uk) 2002-12-16
CN1151741A (zh) 1997-06-11
AU2930595A (en) 1996-02-09
DK0770070T3 (da) 1999-03-01
HU220634B1 (hu) 2002-03-28
TW419473B (en) 2001-01-21
FI970069A0 (fi) 1997-01-07
RU2126397C1 (ru) 1999-02-20
IS4411A (is) 1997-01-07
SI0770070T1 (en) 1998-12-31
EP0770070A1 (fr) 1997-05-02

Similar Documents

Publication Publication Date Title
PE8697A1 (es) Procedimiento de preparacion del trihidrato de(2r,3s)-3-tert-butoxicarbonilamino -2-hidroxi-3-fenilpropionato de 4-acetoxi-2o-benzoiloxi-5�,20-epoxi-1,7�,10�-trihidroxi -9-oxo-tax-11-en-13o-ile
PT882154E (pt) Composicao de locao amaciadora utilizacao em papelaria e produto papeleiro obtido
ES2088141T3 (es) Tratamiento de material de biomasa.
FI793195A (fi) Foerfarande foer framstaellning av ett aemne med bakteriostatisk aktivitet
FR2722410B1 (fr) Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
CO4700286A1 (es) PROCEDIMIENTO DE PREPARACION DEL TRIHIDRATO DEL (2R,3S)-3- BENZOILAMINO-2-HIDROXI-3-FENILPROPIONATO DE 4,10-DIACETOXI- 2(alfa)-BENZOILOXI-5(beta),20-EPOXI-1,7(beta)-DIHIDROXI-9- OXO-TAX-11-EN 13(beta)-ILO
ATE208770T1 (de) Verfahren zur herstullung natürlicher 1,3 diol derivate und korrespondierende natürliche 1,3 dioxan derivate
IE822442L (en) Diesel fuel fibre felt production
NO164167C (no) Analogifremgangsmaate for fremstilling av derivater av 4-fenylkinazolin.
ES2120055T3 (es) Procedimiento para la obtencion biotecnologica de alcoholes, aldehidos y acidos carboxilicos.
PL310207A1 (en) Nisatidin containing pharmaceutical agent, method of obtaining nisatidin in its specific form and specific form of nisatidin as such
SU1791978A1 (ru) Кормовая добавка
JPS54144319A (en) Novel aminoglucopyranoside derivative its preparation, and oncostatic drugs comprising it as active constituent
FR2705959B1 (fr) Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
ES2094817T3 (es) Procedimiento para la racemizacion de acidos 3-oxo-ciclopentano- o 3-oxo-ciclohexano-carboxilicos no racemicos, o de sus esteres con alcoholes c1-c6.
ECSP961646A (es) PROCESO DE PREPARACION DEL TRIHIDRATO DE (2R,3S)-3-BENZOYLAMINO - 2 - HIDROXI - 3 - FENIL-PROPIONATO DE 4, 10 - DIACETOXI - 2 a- BENZOYLOXI - 5ß, 20 - EPOXI- 1, 7ß - DIHIDROXI - 9 - OXO - TAX - 11 - EN - 13 ßYLE
KR880013465A (ko) 인분사료 제조방법

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term